Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
AssigneeAMBI Inc.
InventorsMichael Climo, Ellen Murphy, Gordon Archer
Life of this patent
Estimating the term…
Abstract
Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include β-lactams and glycopeptides.
Claims10
A pharmaceutical composition in dosage form for treating a staphylococcal infection in a human subject, said composition comprising:
- lysostaphin in an amount of from 15 to 150 mg/kg body weight of the human subject;
- and
- a β-lactam antibiotic in an amount of from 50 to 250 mg/kg body weight of the human subject,
- wherein said composition, when administered to the human subject for a period of time sufficient to eradicate said infection, suppresses formation of staphylococcal strains resistant to said lysostaphin, said cell-wall active antibiotic and said composition, and wherein said amount of lysostaphin is an amount effective in treating, in a human, a staphylococcal infection that is not lysostaphin-resistant and wherein said amount of the cell-wall active antibiotic is an amount effective in treating, in a human, a staphylococcal infection that is not resistant to the cell-wall active antibiotic.
Dependencies are inferred from the claim text.